4.7 Article

A cross-sectional study of bone health in multiple sclerosis

期刊

NEUROLOGY
卷 73, 期 17, 页码 1394-1398

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e3181beece8

关键词

-

资金

  1. Consortium of Multiple Sclerosis Centers
  2. BioMS Medical
  3. Sanofi-Aventis
  4. Bayer Schering Pharma (Berlex)
  5. EMD Serono, Inc.
  6. Manitoba Health Research Council
  7. University of Manitoba (Rudy Falk Clinician Scientist)
  8. Health Sciences Centre Foundation
  9. Multiple Sclerosis Society of Canada
  10. Multiple Sclerosis Scientific Foundation
  11. Millenium Pharmaceuticals, Inc.
  12. Klein Buendel, Inc.
  13. Alexion Pharmaceuticals, Inc.
  14. Androclus Therapeutics, Inc.
  15. University of Illinois, Amgen
  16. New York University
  17. Somnus Therapeutics, Inc.
  18. ApopLogic Pharmaceuticals, LLC
  19. NIH [NINDS] [5U01NS042685-02]
  20. NINDS [U01 NS45719-01A1, 1UO1NS45719-02 A1]
  21. NIAID [HHSN266200400068C, N01AI30025]
  22. NHLBI [5R01 HL06991-02, 5P50HL084923-030001]
  23. NIAID
  24. NIDR [3R01DE016684-03S109]
  25. NIDDK [1R01DK078826, 1P30DK079337]
  26. Consortium of Multiple Sclerosis Centers [Director NARCOMS Data Center]
  27. National Multiple Sclerosis Society
  28. President of Pythagoras, Inc
  29. Teva Pharmaceuticals Industries Ltd.,
  30. Daiichi Sankyo, Genzyme Corporation, Ono Pharmaceutical Co., Ltd.
  31. Eli Lilly and Company
  32. Sanofi-Aventis, BioMS Medical, Novartis, PDL BioPharma, Inc.
  33. Pfizer Inc
  34. Merck Serono S. A., Accorda Therapeutics, Genentech, Inc.
  35. NIH [NO1-AL015416/CFDA 93ZZZ]
  36. Barrow Neurological Foundation
  37. Translational Genomics Research Institute
  38. Rocky Mountain Multiple Sclerosis Society

向作者/读者索取更多资源

Background: Osteoporosis is an important risk factor for fragility fractures. Although osteoporosis is considered common in multiple sclerosis (MS), few previous studies focused on fractures in MS. Objective: Using the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry, we investigated the frequency of osteoporosis, fractures, and clinical risk factors for fracture in MS. Methods: In 2007, 9,346 NARCOMS participants reported fractures and clinical risk factors for fractures including history of osteoporosis or osteopenia (low bone mass), sedentary level of physical activity, falls in the last year, current smoking status, family history of osteoporosis, and impaired mobility. Results: Among responders, 2,501 (27.2%) reported low bone mass. More than 15% of responders reported a history of fracture after age 13 years (n = 1,482). Among those reporting fractures, 685 (46.2%) reported multiple fractures, while 522 (35.2%) reported a wrist fracture, 165 (11.1%) reported a vertebral fracture, and 100 (7.4%) reported a hip fracture. Excluding age, 1,413 (15.1%) participants had 1 clinical risk factor for fracture, 2,341 (25.0%) had 2, and 5,393 (57.7%) had 3 or more. Among participants with a history of fracture, 746 (55%) reported taking calcium supplements, 858 (68.8%) reported taking vitamin D supplements or a multivitamin with vitamin D, and 334 (22.5%) reported taking a bisphosphonate. Conclusion: Patients with multiple sclerosis (MS) often have multiple risk factors for osteoporotic fractures. Many patients with MS with low bone mass or previous fractures are not taking supplemental calcium or vitamin D, suggesting a potential area of improvement in care. Neurology (R) 2009;73:1394-1398

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据